|(what is this?)|
Piperacillin/tazobactam is a combination antibiotic containing the extended-spectrum penicillin antibiotic piperacillin and the β-lactamase inhibitor tazobactam. It is commercially available as Tazocin (Canada, UK, Australia and New Zealand, Italy, marketed by Pfizer), and Zosyn (U.S., by Pfizer inc) as well as a generic drug. The combination has activity against many Gram-positive and Gram-negative pathogens and Pseudomonas aeruginosa.
Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections, and empirical therapy in febrile neutropenia (e.g., after chemotherapy). The drug is administered intravenously every 6 or 8 hr, typically over 30 min. It may also be administered by continuous infusion over four hours. Prolonged infusions are thought to maximize the time that serum concentrations are above the minimum inhibitory concentration (MIC) of the bacteria implicated in infection.
The most common adverse reaction is diarrhea (7% to 11%). One study showed Clostridium difficile-associated diarrhea happened in 4.9% of the patients on piperacillin/tazobactam. One other side effect is inhibition of platelets (thrombocytopenia).
Apart from Tazocin and Zosyn, the drug is marketed in various countries under names such as Brodactam, Piptaz, Maxitaz, Kilbac, Trezora, and Biopiper TZ, Du-Tazop by Parabolic drugs (india) .
- "Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients - National Library of Medicine - PubMed Health".
- Yeung, EYH; Gore JG; Auersperg EV (2012). "A Retrospective Analysis of the Incidence of Clostridium Difficile Associated Diarrhea with Meropenem and Piperacillin-tazobactam" (PDF). International Journal of Collaborative Research on Internal Medicine & Public Health 4 (8): 1567–1576.